India accounts for 60 percent of worldwide vaccine production, making it the largest vaccine producer in the world.
India is also one of the world’s biggest suppliers of low-cost vaccines and the largest provider of generic medicines globally, accounting for a 20 percent share in global supply by volume.
India also has the highest number of USFDA-compliant pharmaceutical plants outside of the United States, as well as home to over 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities, and a highly-skilled workforce.
Here are three pharma stocks under Rs. 200 that have delivered multibagger returns of up to 173 percent in the last one year.
Sigachi Industries Limited
The share price of the company in the morning trading session moved up by nearly 2.6 percent on BSE to Rs. 67.95 on April 12th, compared to its previous closing price of Rs. 66.2 and has a market cap of Rs. 2,153 crore.
It has delivered positive returns of about 68.2 percent in the past six months and nearly 176 percent of multibagger returns in the last one year. So far, the company has given around 29.5 percent of positive returns in 2024.
In terms of financials, the company’s revenue from operations grew by nearly 60.8 percent YoY from Rs. 69 crore in Q3 FY22-23 to Rs. 111 crore in Q3 FY23-24, accompanied by an increase in the net profit of 60 percent YoY, from Rs. 10 crore in Q3 FY22-23 to Rs. 16 crore in Q3 FY23-24.
Incorporated in 1989, Sigachi Industries Limited is the industry leader in the field of Pharma Excipients, Nutra and food ingredients and is one of the largest manufacturers of Microcrystalline Cellulose worldwide.
Suven Life Sciences Limited
With a market cap of Rs. 2,597.3 crores, the share price of the company moved up by 1.3% on BSE to Rs. 118.87 in the morning trading session of Friday, compared to its previous closing price of Rs. 117.34.
The company has delivered about 100 percent multibagger returns in the last one year and positive returns of nearly 61.7 percent in the last six months. So far in 2024, it has given positive returns of around 41.2 percent.
In terms of financials, the company’s revenue from operations fell by nearly 33.3 percent YoY from Rs. 3 crore in Q3 FY22-23 to Rs. 2 crore in Q3 FY23-24.
The net profit of Suven Life Sciences is Rs. -42 crore in Q3 FY23-24, an increase of 17.6 percent YoY, from a loss of Rs. 51 crore in Q3 FY22-23.
Incorporated in 1989, Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
Syncom Formulations (India) Limited
With a market capitalisation of Rs. 1,232.3 crores, the share price of the company moved down by nearly 0.37% on BSE to Rs. 13.2 in the morning trading session on Friday, compared to its previous closing price of Rs. 13.25.
The company has delivered about 101.6 percent multibagger returns in the last one year and positive returns of nearly 46.6 percent in the last six months. However, so far in 2024, it has given negative returns of around 17.1 percent.
In terms of financials, the company’s revenue from operations grew by nearly 13.5 percent YoY from Rs. 57.38 crore in Q3 FY22-23 to Rs. 65.14 crore in Q3 FY23-24, accompanied by an increase in the net profit of 69.08 percent YoY, from Rs. 4.14 crore in Q3 FY22-23 to Rs. 7 crore in Q3 FY23-24.
Syncom Formulations (India) Limited manufactures and markets more than 500 products in various dosage forms including tablets, capsules, liquids orals, ophthalmic preparations, dry syrups and suspensions, ointments, creams, and gel.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
